Remove Healthcare Remove Initial Public Offering Remove Mergers and Acquisitions
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

billion acquisition of Alpine Immune; by contrast, there were eight US biotech acquisitions exceeding $5 billion in 2023. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines. from 2023. [1]

M&A 64
article thumbnail

Navigating the Evolving Landscape: Emerging Trends in M&A

Sun Acquisitions

In the dynamic world of mergers and acquisitions (M&A), staying ahead of the curve is crucial for success. As a result, ESG criteria are being integrated into due diligence processes, investment evaluations, and post-merger integration strategies.

M&A 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

For example, in the biopharma space, AbbVie, Bristol Myers Squibb, AstraZeneca, and Roche each announced multiple big-ticket acquisitions in the fourth quarter – including Abbvie’s acquisition of ImmunoGen for $10.1 billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion and Cerevel Therapeutics for $8.7

M&A 52
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves.

M&A 52
article thumbnail

The Re-Evolution of SPACs: Navigating a Maturing Market

MergersCorp M&A International

Special Purpose Acquisition Companies (SPACs), once hailed as the “blank check” path to public markets, have experienced a rollercoaster ride over the past few years. This acquisition, known as a “de-SPAC” transaction, effectively takes the private company public without undergoing the traditional IPO process.

IPO 52